子宫内膜转录组分析后调整黄体酮给药不改善子宫腺肌病女性的生殖结局
这项多中心回顾性队列研究对子宫腺肌病女性(n=81)和健康女性(n=231)的子宫内膜进行转录组分析,发现腺肌病组非容受性子宫内膜比例显著高于健康组(53.1% vs 37.2%,P=0.0179)。在既往一次着床失败并使用供卵的腺肌病患者中,接受(n=59)与未接受(n=66)基于子宫内膜容受性的个体化胚胎移植(PET)者,着床率、生化妊娠流产率、临床流产率及活产率均无显著差异。结论认为调整黄体酮并未改善IVF结局。
要点
- 子宫腺肌病患者非容受性子宫内膜比例显著高于健康女性(53.1% vs 37.2%,P=0.0179)。
- 腺肌病患者子宫内膜非容受性风险升高42.59%(95%CI 41.50至44.45)。
- 基于转录组调整黄体酮的PET未显著改善腺肌病患者的IVF结局。
核心结论
- 子宫腺肌病女性蜕膜化相关基因表达改变,非容受性子宫内膜状态比例高于对照。
- 尽管黄体酮对着床不可或缺,但根据子宫内膜转录组特征在PET前调整黄体酮并未改善腺肌病患者的IVF结局。
- 除黄体酮调控外的其他分子机制可能参与着床失败。
研究设计与样本
- 多中心回顾性队列研究,对子宫腺肌病患者(n=81)和健康女性(n=231)的子宫内膜进行转录组容受性分析。
- 随后观察既往一次着床失败并使用供卵的腺肌病患者中,接受(n=59)与未接受(n=66)基于子宫内膜容受性的PET者的着床率、生化妊娠流产率、临床流产率及活产率。
主要发现
- 腺肌病患者非容受性子宫内膜比例为53.1%,健康患者为37.2%(P=0.0179)。
- 腺肌病患者子宫内膜非容受性风险升高42.59%(95%CI 41.50至44.45)。
- 接受PET组与未接受PET组的着床率分别为62.7%与78.8%(P=0.0514),无显著差异。
- 接受PET组与未接受PET组的生化妊娠流产率分别为13.5%与3.9%(P=0.1223),无显著差异。
- 接受PET组与未接受PET组的临床流产率分别为10.8%与15.4%(P=0.7543),活产率分别为75.7%与80.8%(P=0.6066),均无显著差异。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RESEARCH QUESTION: Do patients with adenomyosis present a dysregulated endometrial receptivity that can be reversed with personalized embryo transfer (PET) by transcriptomic-based progesterone adjustment, improving IVF outcomes? DESIGN: A multicentre, retrospective, cohort study that transcriptomically analysed the endometrial receptivity of the endometrium in patients with adenomyosis (n = 81) and healthy women (n = 231). Subsequently, implantation, biochemical and clinical miscarriage, and live birth rates between adenomyosis patients with one previous implantation failure using donor oocytes who received (n = 59) or did not receive (n = 66) PET based on endometrial receptivity, were observed to evaluate if adjusted progesterone improves reproductive outcomes of adenomyosis patients. RESULTS: Patients with adenomyosis significantly presented an altered endometrial receptivity (non-receptive) compared with healthy patients (53.1% versus 37.2%, P = 0.0179), elevating the risk of adenomyosis patients having a non-receptive endometrium 42.59% higher (95% CI 41.50 to 44.45). No significant differences were found in implantation (62.7% versus 78.8%, P = 0.0514), biochemical (13.5% versus 3.9%, P = 0.1223) and clinical (10.8% versus 15.4%, P = 0.7543) miscarriage, or live birth rates (75.7% versus 80.8%, P = 0.6066), in patients with PET compared with those without PET. CONCLUSIONS: Women with adenomyosis presented an altered expression of genes involved in decidualization, and a higher rate of non-receptive endometrial statuses than controls. Although progesterone is indispensable for implantation, adjusting progesterone before PET, using endometrial transcriptomic signatures, does not improve IVF outcomes in patients with adenomyosis. Other molecular mechanisms beyond progesterone regulation may be involved in implantation failure.
引用
- Juárez-Barber E, Cozzolino M, Corachán A, et al. Adjustment of progesterone administration after endometrial transcriptomic analysis does not improve reproductive outcomes in women with adenomyosis. Reprod Biomed Online. 2022. PMID: 36229390. doi:10.1016/j.rbmo.2022.09.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。